Issue 6/2009
Content (14 Articles)
Targets for active immunotherapy against pediatric solid tumors
J. F. M. Jacobs, P. G. Coulie, C. G. Figdor, G. J. Adema, I. J. M. de Vries, P. M. Hoogerbrugge
Immune activation in advanced cancer patients treated with recombinant IL-21: multianalyte profiling of serum proteins
Michael G. Dodds, Klaus Stensgaard Frederiksen, Kresten Skak, Lasse Tengbjerg Hansen, Dorthe Lundsgaard, John A. Thompson, Steven D. Hughes
Role of the inhibitory KIR ligand HLA-Bw4 and HLA-C expression levels in the recognition of leukemic cells by Natural Killer cells
Sonja Verheyden, Soldano Ferrone, Arend Mulder, Frans H. Claas, Rik Schots, Barbara De Moerloose, Yves Benoit, Christian Demanet
Apoptosis of CD4+CD25high T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2
Kerrington R. Molhoek, Chantel C. McSkimming, Walter C. Olson, David L. Brautigan, Craig L. Slingluff Jr
The immunosuppressive tumor microenvironment in hepatocellular carcinoma
Yan-Li Pang, Hua-Gang Zhang, Ji-Run Peng, Xue-Wen Pang, Shu Yu, Qiao Xing, Xin Yu, Lei Gong, Yan-Hui Yin, Yu Zhang, Wei-Feng Chen
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
Florian Schuetz, Katrin Ehlert, Yingzi Ge, Andreas Schneeweiss, Joachim Rom, Natalija Inzkirweli, Christoph Sohn, Volker Schirrmacher, Philipp Beckhove
Short-term activation induces multifunctional dendritic cells that generate potent antitumor T-cell responses in vivo
Cornelia Wurzenberger, Viktor H. Koelzer, Susanne Schreiber, David Anz, Angelika M. Vollmar, Max Schnurr, Stefan Endres, Carole Bourquin
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells
Panagiotis Karagiannis, Josef Singer, James Hunt, Samuel K. E. Gan, Sarah M. Rudman, Diana Mechtcheriakova, Regina Knittelfelder, Tracy R. Daniels, Philip S. Hobson, Andrew J. Beavil, James Spicer, Frank O. Nestle, Manuel L. Penichet, Hannah J. Gould, Erika Jensen-Jarolim, Sophia N. Karagiannis
Focal adhesion kinase as an immunotherapeutic target
Hiroya Kobayashi, Makoto Azumi, Yuka Kimura, Keisuke Sato, Naoko Aoki, Shoji Kimura, Masaru Honma, Hajime Iizuka, Masatoshi Tateno, Esteban Celis
Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells
Johanna K. Morales, Maciej Kmieciak, Laura Graham, Marta Feldmesser, Harry D. Bear, Masoud H. Manjili
Chronic lymphocytic leukemia (CLL) cells genetically modified to express B7-1, ICAM-1, and LFA-3 confer APC capacity to T cells from CLL patients
Mary T. Litzinger, Kenneth A. Foon, Helen Sabzevari, Kwong-Yok Tsang, Jeffrey Schlom, Claudia Palena
HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody
Wei Wang, Yasuhiko Nishioka, Shuji Ozaki, Ali Jalili, Shinji Abe, Soji Kakiuchi, Masatoshi Kishuku, Kazuo Minakuchi, Toshio Matsumoto, Saburo Sone
Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy
Xiaochuan Chen, Wentao Gao, Andrea Gambotto, Olivera J. Finn
Low representation of Fc receptor-like 1–5 molecules in leukemic cells from Iranian patients with acute lymphoblastic leukemia
Tohid Kazemi, Hossein Asgarian-Omran, Ali Memarian, Mahdi Shabani, Ramazan A. Sharifian, Parvaneh Vossough, Bita Ansaripour, Hodjatallah Rabbani, Fazel Shokri